Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007651 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT06007651 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 49 participants.
The verdict
NCT06007651, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with non-alcoholic fatty liver disease (part B). Blood tests will be performed to check how much LY3885125 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 49 weeks for part A and 62 weeks for part B, for a total of approximately 111 weeks.
Interventions
- DRUG Placebo
- DRUG LY3885125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-08-10 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06007651
The ClinicalTrials.gov registry entry for NCT06007651 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06007651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06007651 about?
NCT06007651 is a clinical study titled "A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)". The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with non-alcoholic fatty liver disease (part B). Blood tests will be performed to check ...
What is the current status of trial NCT06007651?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2023-08-10. Estimated completion is 2025-02-12.
What interventions are being tested in trial NCT06007651?
The interventions under investigation include: Placebo (DRUG), LY3885125 (DRUG).
Who is sponsoring clinical trial NCT06007651?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.